[203Pb]VMT-α-NET

Phase 1Active

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neuroendocrine Tumor Grade 2

Conditions

Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1

Trial Timeline

Aug 22, 2022 → Jun 30, 2026

NCT ID

NCT05111509

About [203Pb]VMT-α-NET

[203Pb]VMT-α-NET is a phase 1 stage product being developed by Perspective Therapeutics for Neuroendocrine Tumor Grade 2. The current trial status is active. This product is registered under clinical trial identifier NCT05111509. Target conditions include Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1.

What happened to similar drugs?

6 of 16 similar drugs in Neuroendocrine Tumor Grade 2 were approved

Approved (6) Terminated (2) Active (9)

✅Everolimus (RAD001)NovartisApproved

✅Pasireotide + DiazoxideNovartisApproved

✅everolimusNovartisApproved

✅sunitinibPfizerApproved

✅lanreotide acetateIpsenApproved

✅lanreotide (Autogel formulation)IpsenApproved

🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05111509	Phase 1	Active	Aug 22, 2022	Jun 30, 2026	Neuroendocrine Tumor Grade 2

Competing Products

20 competing products in Neuroendocrine Tumor Grade 2

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27
Lenvatinib	Eisai	Phase 2	35
Abemaciclib	Eli Lilly	Phase 2	39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.	Jiangsu Hengrui Medicine	Phase 3	47
Famitinib	Jiangsu Hengrui Medicine	Phase 2	27
68Ga-DOTATOC	Jiangsu Hengrui Medicine	Phase 3	47
Olaparib	AstraZeneca	Phase 2	27
Avelumab	Merck	Phase 1/2	32
Pembrolizumab	Merck	Phase 2	27
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	35
Pembrolizumab Injection	Merck	Phase 2	27
Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab	Merck	Phase 1	33
Avelumab	Merck	Phase 2	35
Pembrolizumab + Lenvatinib	Merck	Phase 2	35
Avelumab	Merck	Phase 2	35
Pembrolizumab + Irinotecan + Paclitaxel	Merck	Phase 2	35
MK-0646	Merck	Phase 2	35
Lanreotide + Pembrolizumab	Merck	Phase 1/2	32